Navigation Links
Butamax Announces Immediate Appeal of Court Decisions on Claim Construction and Summary Judgment
Date:3/20/2013

WILMINGTON, Del., March 20, 2013 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC, the leading biobutanol technology company, announced today it would appeal the Court's claim construction and decisions on certain motions before the Court in Butamax's litigation against Gevo.

Paul Beckwith , Butamax Chief Executive Officer, stated, "Butamax has decided to appeal this case immediately.  Butamax strongly disagrees with the Court's claim construction.  We do not believe it is consistent with either the patent, rules for patent claim construction or statements made by the Federal Circuit.  We have therefore decided to appeal immediately to resolve this matter before going to trial.  We are confident the Federal Circuit will determine this matter in our favor."

The Court made no overall determination on literal infringement and denied Gevo's motions of invalidity on all but two of 37 patent claims being asserted by Butamax against Gevo.  However, despite previous statements from the Federal Circuit, the Court chose a very narrow claim construction for the KARI enzyme element of the claims.  This narrow interpretation, in Butamax's view, is in error as a matter of law and therefore Butamax is taking this claim construction immediately back to the Federal Circuit for appeal.

Beckwith continues, "This is still an early stage in what is likely to be a long and complicated litigation, involving many patents that will take several years for the courts to resolve.   Butamax is currently enforcing six other patents against Gevo and will vigorously continue to do so while this case is appealed."

Butamax remains strongly committed to near term commercialization of its biobutanol technology.  Butamax will continue its strategy of bringing advanced biofuels to the consumer and providing a real solution to the blendwall.

About Butamax 

Butamax™ Advanced Biofuels, LLC was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:  
Mark Buse  202-679-5576 
Mark.Buse@butamax.com

 


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
4. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
5. USPTO Grants Butamax a Further KARI Enzyme Patent
6. Gevo Doesnt Infringe Butamaxs 017 Patent; Gevo was First to Invent Enzyme in 017 Patent; Gevo has Advanced Beyond That and Now Uses Different Enzymes
7. Appeal Courts Direction on Claim Construction Is Strategically Important for Butamaxs Case Against Gevo Scheduled for April 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
10. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
11. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and ... they have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas ... tools for gene editing across all applications. , Under the terms of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity of ... performing systematic gain-of-function studies. , This complement to loss-of-function studies, such as ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
Breaking Biology News(10 mins):